Company intelligence / Profile preview
Ironfist Therapeutics
Boston, Massachusetts, United Statesironfisttx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Ironfist Therapeutics is a pre-clinical stage biotechnology company focused on developing novel immunotherapies for hematologic malignancies. The company's primary focus is on targeting T-cell immunoglobulin and mucin-domain containing-3 (TIM-3), a key immune checkpoint receptor expressed on both immune cells and leukemic stem cells. By developing high-affinity monoclonal antibodies, Ironfist aims to eliminate cancer stem cells while simultaneously reinvigorating the host immune response. Their lead programs are currently being evaluated for the treatment of acute myeloid leukemia and high-risk myelodysplastic syndromes.
- Therapeutic areas
- HematologyOncology
- Modalities
- Monoclonal antibodyAntibody
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on Ironfist Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ironfist Therapeutics.